Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study

Pain Clinical Trial

Official title: High-dose Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study

Status Completed

Clinical Trial Summary

The purpose of this study is to show the clinical usefulness of fentanyl matrix by measuring satisfaction with pain treatment after administering fentanyl matrix in patients whose pain was not controlled sufficiently with the previous analgesic use in real practice at the investigator's discretion.

Clinical Trial Description

This is a multi-center, open-label (all people know the identity of the intervention), prospective (the patients are identified and then followed forward in time for the outcome of the study) observational study. The study population comprises patients who are admitted to a study center during the study period and are receiving a strong oral long-acting opioid analgesic but deemed to control pain insufficiently. Since this study is an observational study conducted in real practice, a dose of fentanyl matrix should be adjusted depending on an individual patient's response at the investigator's discretion. However, for the patients whose pain is not sufficiently controlled despite administration of strong long-acting opioid analgesics, the minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust dosage according to the degree of the patients' pain control during the 9 days of the study period. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Pain

• NCT number: NCT01816503
• Study type: Observational
• Source: Janssen Korea, Ltd., Korea
• Status: Completed
• Phase: Phase 4
• Start date: December 2008
• Completion date: July 2009